Rajesh Agrawal

Our new product contribution within that is 4.7% out of 13%, as against the industry which stands at 2.8% out of 10%.

We continue to outperform the Indian pharmaceutical market by 28% as per IQVIA MAT December 2025, with Ajanta delivering an impressive growth of 11% compared to IPM's 9%.

We've never seen a launch of a product like this in the longest time. Already, globally, it's become, I think, what? $35-$40 billion and $25 billion each, $50 billion. And it's still growing at 25%-30%.

We continue to outperform the Indian pharmaceutical market by 28% as per IQVIA MAT December 2025 with Ajanta delivering an impressive growth of 11% compared to IPM's 9%.

We are looking to start filing the dossier from Q1 in all our markets and from 12 months onwards we should start getting the approvals in various countries.

We are in talks with IQVIA to see how this anomaly can be taken out... I'm not too worried.

I think the correct way to look at would be to see what is the growth we are posting on the top line and the bottom line. That would be the correct measure instead of focusing purely on the expansion of the margin.

We are in talks with IQVIA to see how this anomaly can be taken out and what could be the reasons why there is such a big gap.

We continue to outpace the IPM and the Indian Pharmaceutical Market by 29% as per IQVIA MAT June 2025 with Ajanta delivering an impressive growth of 10% compared to IPM's 8% growth.

We continue to outpace IPM by 300 basis points, with Ajanta growing at 11%, surpassing IPM growth of 8% as per IQVIA MAT December 2024.

Our faster growth is contributed mainly by volumes, which was about 1.5 times to the IPM.

Our performance has been excellent on the back of increased volumes, price increase, and new product launches.